Democrats urge HHS to 'march-in' or enable 'government-use' rights to make Xtandi less expensive
HHS should move forward with a recent petition to allow the government to exercise its “march-in” rights to lower the price of Astellas and Pfizer’s cancer drug Xtandi, known generically as enzalutamide, Sens. Elizabeth Warren (D-MA) and Angus King (I-ME), and Rep. Lloyd Doggett (D-TX) said in a letter to HHS Secretary Xavier Becerra late last week.
If NIH continues to decide to never use its march-in rights under the Bayh-Dole Act, the Democrats note that the federal government can also exercise its government-use rights to permit generic competition with Xtandi.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,400+ biopharma pros reading Endpoints daily — and it's free.